Effects of methimazole on the elimination of irinotecan

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 1, 2011, Pages 231-236

  Van Der Bol, Jessica M ^a   Visser, Theo J ^a   Loos, Walter J ^a   De Jong, Floris A ^a   Wiemer, Erik A C ^a   Van Aken, Maarten O ^a   Planting, Andre S ^a   Schellens, Jan H ^b,c   Verweij, Jaap ^a   Mathijssen, Ron H J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

CYP3A; Diarrhea; Drug interaction; Irinotecan; Methimazole; SN 38; UGT1A

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; GLUCURONOSYLTRANSFERASE 1A1; IODINE 131; IRINOTECAN; LEVOTHYROXINE; LIOTHYRONINE; THIAMAZOLE; THYROTROPIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG GLUCURONIDATION; FOLLOW UP; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTITHYROID AGENTS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG INTERACTIONS; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; GRAVES DISEASE; HUMANS; MALE; METHIMAZOLE; MIDDLE AGED;

EID: 78651106484     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1414-x     Document Type: Article

References (20)

1. U Vanhoefer A Harstrick W Achterrath S Cao S Seeber YM Rustum 2001 Irinotecan in the treatment of colorectal cancer: clinical overview J Clin Oncol 19 1501 1518 1:CAS:528:DC%2BD3MXit1ertb8%3D 11230497 (Pubitemid 32202559)
2. A Di Paolo G Bocci R Danesi M Del Tacca 2006 Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients Curr Clin Pharmacol 1 311 323 1:CAS:528:DC%2BD28XpvFOnsbc%3D 10.2174/157488406778249307 18666754
3. F Innocenti DL Kroetz E Schuetz ME Dolan J Ramirez M Relling P Chen S Das GL Rosner MJ Ratain 2009 Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics J Clin Oncol 27 2604 2614 1:CAS:528: DC%2BD1MXnslWit70%3D 10.1200/JCO.2008.20.6300 19349540
4. FA de Jong A Sparreboom J Verweij RH Mathijssen 2008 Lifestyle habits as a contributor to anti-cancer treatment failure Eur J Cancer 44 374 382 10.1016/j.ejca.2007.12.012 18207386
5. RH Mathijssen J Verweij P de Bruijn WJ Loos A Sparreboom 2002 Effects of St. John's wort on irinotecan metabolism J Natl Cancer Inst 94 1247 1249 1:CAS:528:DC%2BD38XntVyjsL8%3D 12189228
6. JM van der Bol RH Mathijssen WJ Loos LE Friberg RH van Schaik MJ de Jonge AS Planting J Verweij A Sparreboom FA de Jong 2007 Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia J Clin Oncol 25 2719 2726 10.1200/JCO.2006.09.6115 17563393 (Pubitemid 47123179)
7. Z Guo S Raeissi RB White JC Stevens 1997 Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes Drug Metab Dispos 25 390 393 9172960
8. TJ Visser E Kaptein A Gijzel WW de Herder ML Cannon F Bonthuis WJ de Greef 1996 Effects of thyroid status and thyrostatic drugs on hepatic glucuronidation of lodothyronines and other substrates in rats Endocrine 4 78 85 10.1007/BF02738878
9. P de Bruijn EW Willems WJ Loos J Verweij A Sparreboom 2004 Indirect determination of the irinotecan metabolite 7-ethyl-10-O-glucuronyl-camptothecin in human samples Anal Biochem 328 84 86 10.1016/j.ab.2004.01.007 15081912 (Pubitemid 38479622)
10. A Sparreboom P de Bruijn MJ de Jonge WJ Loos G Stoter J Verweij K Nooter 1998 Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces J Chromatogr B Biomed Sci Appl 712 225 235 1:CAS:528:DyaK1cXks1Oht7s%3D 10.1016/S0378-4347(98)00147-9 9698245 (Pubitemid 28322438)
11. W Van Steenbergen J Fevery R De Vos R Leyten KP Heirwegh J De Groote 1989 Thyroid hormones and the hepatic handling of bilirubin. I. Effects of hypothyroidism and hyperthyroidism on the hepatic transport of bilirubin mono- and diconjugates in the Wistar rat Hepatology 9 314 321 10.1002/hep.1840090225 2536351 (Pubitemid 19063320)
12. DF Kehrer RH Mathijssen J Verweij P de Bruijn A Sparreboom 2002 Modulation of irinotecan metabolism by ketoconazole J Clin Oncol 20 3122 3129 1:CAS:528:DC%2BD38XmtVCrtb0%3D 10.1200/JCO.2002.08.177 12118026 (Pubitemid 34791102)
13. PJ Tobin P Beale L Noney S Liddell LP Rivory S Clarke 2006 A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer Cancer Chemother Pharmacol 57 309 316 1:CAS:528:DC%2BD28XislWkurk%3D 10.1007/s00280-005-0053-0 16003560
14. K Takasuna T Hagiwara M Hirohashi M Kato M Nomura E Nagai T Yokoi T Kamataki 1996 Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats Cancer Res 56 3752 3757 1:CAS:528: DyaK28XltVKksL4%3D 8706020
15. K Takasuna T Hagiwara M Hirohashi M Kato M Nomura E Nagai T Yokoi T Kamataki 1998 Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats Cancer Chemother Pharmacol 42 280 286 1:CAS:528:DyaK1cXls1Wlt7c%3D 10.1007/s002800050818 9744772 (Pubitemid 28393844)
16. R Xie RH Mathijssen A Sparreboom J Verweij MO Karlsson 2002 Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea Clin Pharmacol Ther 72 265 275 1:CAS:528:DC%2BD38XotVSmur8%3D 10.1067/mcp.2002.126741 12235447
17. DF Kehrer A Sparreboom J Verweij P de Bruijn CA Nierop J van de Schraaf EJ Ruijgrok MJ de Jonge 2001 Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients Clin Cancer Res 7 1136 1141 1:CAS:528:DC%2BD3MXktlemurY%3D 11350876
18. JG Slatter P Su JP Sams LJ Schaaf LC Wienkers 1997 Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions Drug Metab Dispos 25 1157 1164 1:CAS:528:DyaK2sXmvVWnsLg%3D 9321519
19. WP Yong J Ramirez F Innocenti MJ Ratain 2005 Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes Clin Cancer Res 11 6699 6704 1:CAS:528:DC%2BD2MXhtVShsb3M 10.1158/1078-0432.CCR-05-0703 16166450 (Pubitemid 41339012)
20. H Burger H van Tol AW Boersma M Brok EA Wiemer G Stoter K Nooter 2004 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump Blood 104 2940 2942 1:CAS:528: DC%2BD2cXpslKju7s%3D 10.1182/blood-2004-04-1398 15251980 (Pubitemid 39434984)